Biosimilars Market Access

• Understand how the global pharmaceutical market is becoming more specialized and precise
• Identify what the experience on biosimilars has been so far and assess what role generics and biosimilars play in the future
• Identify which therapeutic areas have been explored and which were most successful for gaining approval and acceptance

• Identify which fundamental lessons were learned from the European experience that apply to the US and which do not
• Define which elements of the U.S. framework will uniquely shape the U.S. market
• Understand what the critical outstanding questions are that be must addressed as an industry in order to best encourage biosimilars in the U.S.

• Assess and discuss the emerging application and approval pathway
• Understand how the purple book will impact biosimilars speed to market
• Address the latest updates on nomenclature, substitution, and interchangeability

As biosimilars, or lower-priced biologics, come to market within the year, how will payers evaluate these drugs beyond price?

• Discuss what payers are looking for in terms of services when they are deciding which biosimilars to put on formulary
• Learn what might influence them to choose one manufacturer over another for the treatment of the same indication
• Analyze the parameters that could determine market access beyond price

• Identify key “operational” barriers that could limit patient access to Biosimilars
• Address the role various stakeholders need to play to reduce these barriers

For many drugs such as specialty oncology drugs, hospital systems hold a lot of power over which drugs get to patients because they are administered right at the hospital. Hear a unique perspective on:

• How many biosimilars hospitals and institutions may plan to include on formulary?
• How are decisions made which products are included on the formulary, especially when there are different products for the same indication?
• What are the barriers to the adoption and usage of biosimilars in practice?

• Leverage co-payment assistance resources and programs for patients who might otherwise not be able to afford biologics treatments
• Build physician confidence through education, experience, and by providing transparency on labeling and appropriate patient types
• Understand how the entrance of the biosimilars era can improve accessibility and affordability for patients